DFX Intelligence
Borrowers
196 borrower groups currently held, grade A and BWhat a borrower group isA borrower group is every spelling of one credit agreement's borrower across the BDCs that hold it (Icefall Parent, Icefall Topco and Icefall Bidco are one). Grade A and B groups are listed; a short one-word stem (grade C) is kept apart and never merged across filers. Principal is the sum of BDC pieces and is a lower bound.Principal and marks are the filers' figures at each BDC's latest quarter end, summed. Maturity is the filer's tagged date or the date written into the identifier; a BDC that tags neither leaves it unstated.
Industry as filed contains “Pharmaceuticals” (remove)
Start from
196 borrower groups
| Borrower | Sponsor | BDCs | Principal held | On cost | Spread | Next maturity | First seen |
|---|---|---|---|---|---|---|---|
| LS Clinical Services Holdings, Inc Life sciences | unattributed | 3 | at least $40.9M | 71c | 0 pts | Jun 18, 2029 | Mar 31, 2022 |
| Project Alliance Buyer, LLC Life sciences | Align Capital Partners, LP inferred | 6 | at least $40.6M | 101c | 1 pts | Apr 30, 2030 | Dec 31, 2024 |
| Opal Bidco SAS Life sciences | unattributed | 5 | at least $38.8M | 100c | 0 pts | Apr 1, 2032 | Mar 31, 2025 |
| A••••• A•••••••• I•• Life sciences | unattributed | 4 | at least $38.7M | 100c | 0 pts | Dec 31, 2031 | Sep 30, 2022 |
| A••••• I••••••••• Life sciences | unattributed | 2 | at least $37.9M | 99c | 0 pts | Jun 1, 2028 | Sep 30, 2022 |
| T•••••• T••••••••• L•• Life sciences | unattributed | 8 | at least $37.6M | 100c | 0 pts | Apr 4, 2030 | Dec 31, 2021 |
| B•••••••• S•••• Life sciences | unattributed | 2 | at least $34.7M | 106c | 1 pts | Feb 26, 2032 | Mar 31, 2025 |
| N•••• H••••••••• H•••••• A• Life sciences | unattributed | 1 | at least $33.0M | 99c | n/a | Feb 1, 2030 | Sep 30, 2025 |
| L••• H•••••••• I•• Life sciences | unattributed | 20 | at least $32.3M | 99c | 1 pts | Feb 23, 2032 | Dec 31, 2021 |
| H•••••• I••••••••• L•• Life sciences | unattributed | 3 | at least $31.6M | 101c | 0 pts | Nov 15, 2028 | Dec 31, 2021 |
| N•••••• Life sciences · grade B | unattributed | 1 | at least $27.6M | 100c | n/a | Nov 1, 2026 | Dec 31, 2022 |
| E••• P••••••••• I•• Life sciences | unattributed | 1 | at least $27.0M | 106c | n/a | Dec 17, 2027 | Jun 30, 2026 |
| P•• P•••• P•• M••••• T•••• L•• Life sciences | unattributed | 1 | at least $26.3M | 98c | n/a | Feb 13, 2032 | Dec 31, 2025 |
| B•••••• O•••• L•• Life sciences | unattributed | 1 | at least $25.9M | 100c | n/a | May 31, 2027 | Jun 30, 2023 |
| P••••••••• H••••• H•••••••• I•• Life sciences | unattributed | 9 | at least $25.3M | 99c | 1 pts | Mar 19, 2032 | Dec 31, 2021 |
| J•••••• M•••••• C••••••••• Life sciences | unattributed | 1 | at least $25.0M | 106c | n/a | Jun 27, 2028 | Jun 30, 2026 |
| S••••• T••••••••• P•• Life sciences | unattributed | 1 | at least $25.0M | 104c | n/a | Sep 28, 2028 | Dec 31, 2025 |
| H••••••••• Life sciences | unattributed | 1 | at least $24.7M | 100c | n/a | Apr 10, 2034 | Jun 30, 2026 |
| U••• H••••• L•• Life sciences | unattributed | 2 | at least $23.8M | 99c | 1 pts | May 26, 2031 | Jun 30, 2025 |
| A•••••• P••••• U•• I•• Life sciences | unattributed | 6 | at least $22.3M | 99c | n/a | Nov 30, 2028 | Dec 31, 2021 |
| U• W•••••••• V•••••••• L•• Life sciences | unattributed | 1 | at least $22.0M | 99c | n/a | Jul 31, 2030 | Sep 30, 2024 |
| L••••••••• S•••••• L•••••• Life sciences | unattributed | 2 | at least $20.4M | 101c | n/a | Dec 23, 2030 | Dec 31, 2024 |
| R•• H•••••••• I•• Life sciences | unattributed | 10 | at least $20.0M | 102c | 0 pts | Dec 23, 2030 | Dec 31, 2021 |
| S••••••• P••••••••• I•• Life sciences | unattributed | 1 | at least $20.0M | 105c | n/a | Aug 31, 2030 | Jun 30, 2026 |
| A••••••• O••••• T••••••• I•• Life sciences | unattributed | 1 | at least $19.5M | 106c | n/a | Feb 15, 2029 | Jun 30, 2026 |
| E•• H••••• Life sciences | unattributed | 2 | at least $18.9M | 100c | 0 pts | Aug 7, 2030 | Sep 30, 2024 |
| T••••••• H••••• C••• P••••••• I•• Life sciences | Sponsor not establishedpossible: N•• W•••• C••••••• L••• (a company of this name is on the sponsor's portfolio page) | 2 | at least $18.8M | 99c | 0 pts | Aug 6, 2031 | Mar 31, 2025 |
| R• E••••••••• L•• Life sciences | unattributed | 6 | at least $18.3M | 102c | 0 pts | Oct 17, 2031 | Dec 31, 2022 |
| N•••••• P••••••••• L•• Life sciences | unattributed | 4 | at least $17.2M | 98c | 5 pts | Dec 30, 2027 | Sep 30, 2023 |
| H••••• B•••• G•••••• G••• Life sciences | unattributed | 2 | at least $16.9M | 98c | 0 pts | Apr 29, 2033 | Jun 30, 2026 |
| B••••••••• Life sciences | unattributed | 1 | at least $16.8M | 88c | n/a | Dec 31, 2028 | Dec 31, 2022 |
| O•• L•• O•••• B••••• L•• Life sciences | unattributed | 2 | at least $16.3M | 92c | 0 pts | Jul 18, 2030 | Sep 30, 2024 |
| W•• G•••• H•••••••• L•• Life sciences | unattributed | 2 | at least $15.7M | 101c | 0 pts | Dec 31, 2029 | Dec 31, 2023 |
| C••••• B•••• S•••••• Life sciences | unattributed | 7 | at least $14.9M | 100c | 1 pts | Aug 1, 2031 | Sep 30, 2022 |
| V••••• B•••• L•••••• Life sciences | unattributed | 2 | at least $14.5M | 99c | 0 pts | Aug 20, 2030 | Sep 30, 2025 |
| A•••• B•••• Life sciences · grade B | unattributed | 1 | at least $14.5M | 98c | n/a | Oct 29, 2032 | Jun 30, 2025 |
| S••••••• P•••• S•••••• B•••• L•• Life sciences | unattributed | 1 | at least $14.5M | 97c | n/a | Sep 24, 2031 | Dec 31, 2025 |
| B•••• S•••• Life sciences | unattributed | 3 | at least $14.4M | 103c | 6 pts | Jun 30, 2031 | Sep 30, 2024 |
| S••••• O•••• Life sciences | Sponsor not establishedpossible: I••••••• C•••••• P•••••••• L•• (a company of this name is on the sponsor's portfolio page) | 2 | at least $14.3M | 101c | 0 pts | Jul 31, 2028 | Dec 31, 2024 |
| E•••• B••••• L•• Life sciences | unattributed | 2 | at least $14.1M | 99c | 0 pts | Mar 12, 2033 | Mar 31, 2026 |
| B•••••• T••••••••• I•• Life sciences | unattributed | 2 | at least $14.0M | 88c | 0 pts | Apr 19, 2027 | Sep 30, 2022 |
| E••• F•••••• H••••••• I•• Life sciences | unattributed | 4 | at least $13.5M | 101c | n/a | Apr 23, 2031 | Jun 30, 2024 |
| N•••• B•••• Life sciences | unattributed | 2 | at least $13.3M | 99c | 0 pts | Jun 24, 2032 | Jun 30, 2025 |
| W••• C••••••••• B••••• L•• Life sciences | unattributed | 2 | at least $13.0M | 100c | 0 pts | Dec 20, 2032 | Dec 31, 2025 |
| B••••• S••••••••• L••••• Life sciences | unattributed | 2 | at least $11.9M | 101c | n/a | Mar 25, 2028 | Jun 30, 2024 |
| A••••• P••••••••• L•• Life sciences | unattributed | 8 | at least $11.6M | 101c | n/a | Aug 1, 2032 | Jun 30, 2024 |
| P•••••••• C•••••••• Life sciences | unattributed | 3 | at least $10.9M | 95c | n/a | Apr 16, 2032 | Sep 30, 2025 |
| S•••••• I••••••••• H•••••••• L•• Life sciences · grade B | unattributed | 1 | at least $10.4M | 95c | n/a | Sep 17, 2030 | Sep 30, 2024 |
| S••••••• P••••• S•••••• B•••• L•• Life sciences | unattributed | 2 | at least $10.3M | 99c | n/a | Sep 24, 2031 | Sep 30, 2024 |
| G•••• E••••••••• D••••• C••••• P• Life sciences | unattributed | 1 | at least $10.0M | 85c | n/a | Sep 30, 2026 | Dec 31, 2021 |
The borrower, lender and sponsor names past the first 3 rows are hidden. Open a row to reveal that record with a free account (5 a month), or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source is public either way.